Nektar Therapeutics Updates on Phase 2b Alopecia Trial
Nektar Therapeutics (NASDAQ: NKTR) has recently announced topline results from the Phase 2b REZOLVE-AA trial, which focuses on the investigational medication rezpegaldesleukin intended to assist patients suffering from severe alopecia areata.
Alopecia Areata: An Overview
Alopecia areata is an autoimmune condition where the body’s immune system mistakenly attacks hair follicles, resulting in sudden hair loss in varying degrees. This condition can lead to partial scalp loss known as alopecia totalis or even complete body hair loss termed alopecia universalis.
The Study Setup
The global Phase 2b study involved 92 patients suffering from severe-to-very-severe alopecia areata. The duration of the treatment period under investigation lasted 36 weeks, during which both primary and secondary endpoints were evaluated effectively.
Key Findings of the Trial
The primary goal was to determine the mean percentage reduction from baseline on the Severity of Alopecia Tool (SALT) score by Week 36. Results showed that both treatment arms significantly outperformed placebo regarding the SALT reduction, with the majority of participants observing hair growth by Week 16 or beyond.
However, the primary endpoint narrowly missed achieving statistical significance. The mean percent reduction at Week 36 was recorded at 28.2% for the 24 µg/kg and 30.3% for the 18 µg/kg rezpegaldesleukin arms, against a 11.2% reduction for placebo (p=0.186 and p=0.121, respectively).
Adjusting for Eligibility Violations
In an interesting twist, four out of 92 patients were identified as having violated critical eligibility criteria for the trial, demonstrating that their randomization into the study was questionable. Removing these individuals from consideration significantly altered the outcome for the rezpegaldesleukin treatment arms, allowing them to meet statistical significance on the primary endpoint.
When these patients were excluded, the mean SALT reduction was reported to be 29.6% for the 24 µg/kg group, 30.4% for the 18 µg/kg group, and just 5.7% for those on placebo (p=0.049 and p=0.042, respectively). Notably, the overall treatment effects remained similar regardless of patient inclusion.
Exploring Secondary Endpoints
Both treatment arms also displayed a dose-dependent clinical improvement beyond the primary target, showcasing notable effects on key secondary outcomes, including SALT scores of ?30, ?20, and ?10.
In addition, patients who exhibited hair growth but had not reached a SALT score greater than 20 were given the opportunity to continue treatment for an additional 16 weeks in a double-blind extension phase, seeking further beneficial results.
Future Prospects
Nektar Therapeutics plans to present these findings at an upcoming medical conference in 2026. Furthermore, data from patients participating in the 16-week treatment extension is anticipated to be available in the early second quarter of the same year.
Broader Context and Related Studies
In September, Nektar also revealed positive data from its REZOLVE-AD Phase 2b study, which assessed the impact of rezpegaldesleukin on atopic dermatitis. The therapy was shown to not only meet its primary endpoint but also yielded statistically significant results across several secondary objectives, including the Eczema Area and Severity Index (EASI).
This backdrop highlights the therapeutic potential of rezpegaldesleukin, supporting a wider interest in Nektar's drug development pipeline.
Nektar's Current Market Position
As of the latest publication, shares of Nektar Therapeutics had decreased by 7.86%, trading at $49.11. This fluctuation reflects the market's immediate reaction to the trial's mixed results and sets the stage for potential future movement based on the outcomes of ongoing studies.
Frequently Asked Questions
What is Nektar Therapeutics focusing on in their recent trial?
Nektar Therapeutics is investigating rezpegaldesleukin for treating severe alopecia areata.
What was the primary endpoint of the REZOLVE-AA trial?
The primary endpoint was the mean percentage reduction in the Severity of Alopecia Tool (SALT) score from baseline at Week 36.
How did the trial results change after excluding certain patients?
Excluding four patients with eligibility violations allowed both treatment arms to achieve statistical significance on the primary endpoint.
What secondary outcomes were observed in the trial?
Patients on rezpegaldesleukin showed dose-dependent improvements on secondary SALT score endpoints.
When will further data from the ongoing treatment extension be available?
Further data is expected to be released in the early second quarter of 2026.
